Napredna pretraga

Pregled bibliografske jedinice broj: 878652

Price Dynamics of Hepatitis C Virus Therapies in Croatia


Mance, Diana; Mance, Davor; Vitezić, Dinko
Price Dynamics of Hepatitis C Virus Therapies in Croatia // Value in Health, Volume 20, Number 5, May 2017, ISPOR 22nd Annual International Conference Research Abstracts / Drummond, Michael ; Mullins, C. Daniel (ur.).
Boston, MA, USA: Elsevier, 2017. str. A182-A182 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Price Dynamics of Hepatitis C Virus Therapies in Croatia

Autori
Mance, Diana ; Mance, Davor ; Vitezić, Dinko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Value in Health, Volume 20, Number 5, May 2017, ISPOR 22nd Annual International Conference Research Abstracts / Drummond, Michael ; Mullins, C. Daniel - : Elsevier, 2017, A182-A182

Skup
ISPOR 22nd Annual International Conference

Mjesto i datum
Boston, MA, USA, 20.-24.05.2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
HCV drug price dynamics

Sažetak
OBJECTIVES: To investigate and explain changes of drug prices for hepatitis C virus (HCV) treatments on the Croatian market. METHODS: The study is a retrospective analysis, conducted using publicly available pricing lists from the Croatian National Health Insurance Fund. The encompassed period is from November 2012 to July 2016. RESULTS: Pegylated interferon alpha- 2a (pegIFN) maintained a constant price for a longer period of time due to the lack of direct competition. Boceprevir (BOC) and telaprevir (TPV) were able to maintain a constant price since their entry on the market up until simeprevir (SIM) entered the EU5 (Germany, France, United Kingdom, Italy, and Spain) market. Consequently, prices of TPV and BOC dropped (6% and 11%, respectively) remaining at that level even after SIM entered the Croatian market. The market entry of sofosbuvir (SOF) and ombitasvir, paritaprevir, ritonavir, and dasabuvir (OBV/PTV/ r/DSV) combination therapy was followed by a significant SIM’s price reduction (19%) and the ultimate withdrawal of TPV. In July 2016 BOC experienced a significant drop of its price (16%) probably due to the fact that BOC is not the standard of care anymore. On the other hand, the SIM, SOF and OBV/PAR/r/DAS price drop in July 2016 was negligible (o1%). A price reductions, similar to price reductions on USA market, could not be observed on the Croatian market. CONCLUSIONS: HCV drug price reductions have not been under direct impact of competition on the Croatian market but they are rather a consequence of competition on the EU5 and USA markets. The Croatian market is a typical market of a small and open economy without independent price setting. The principal reason for that is the Croatian EU membership with the prohibition of price discrimination, as well as a delayed drug introduction to the Croatian market in comparison to USA and EU5 markets.

Izvorni jezik
Engleski

Znanstvena područja
Matematika, Temeljne medicinske znanosti, Ekonomija



POVEZANOST RADA


Ustanove
Medicinski fakultet, Rijeka,
Ekonomski fakultet, Rijeka,
Sveučilište u Rijeci - Odjel za fiziku

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • Social Science Citation Index (SSCI)
  • Scopus
  • MEDLINE